Mitigating preventable chronic disease: Progress report of the Cleveland Clinic's Lifestyle 180 program
- PMID: 22112436
- PMCID: PMC3264524
- DOI: 10.1186/1743-7075-8-83
Mitigating preventable chronic disease: Progress report of the Cleveland Clinic's Lifestyle 180 program
Abstract
Background: Poor lifestyle choices are key in development and progression of preventable chronic diseases. The purpose of the study was to design and test a program to mitigate the physical and fiscal consequences of chronic diseases.
Methods: Here we report the outcomes for 429 participants with one or more chronic conditions, including obesity, hypertension, hyperlipidemia and diabetes mellitus, many of whom had failed traditional disease management programs, who enrolled into a comprehensive lifestyle intervention. The Lifestyle 180 program integrates nutrition, physical activity and stress management interventions and was conducted at the Wellness Institute of the Cleveland Clinic, United States. An intensive 6 week immersion course, with 8 hours of group instruction per week, was followed by 3 follow-up, 4 hour-long sessions over the course of 6 months.
Results: Changes in biometric (weight, height, waist circumference, resting heart rate and blood pressure) and laboratory variables (fasting lipid panel, blood glucose, insulin, hemoglobin A1c, ultra sensitive C-reactive protein) at 6 months were compared with baseline (pre-post analysis). At week 30, biometric and laboratory data were available for 244 (57%) and 299 (70%) participants, respectively. These had a mean ± SD reduction in weight (6.8 ± 6.9 kg, P < 0.001), waist circumference (6.1 ± 7.3 cm, P < 0.001), glucose (4.5 ± 29.6 mg/dL or 0.25 ± 1.64 mmol/L, P = 0.009), triglycerides (26.4 ± 58.5 mg/dL or 0.30 ± 0.66 mmol/L, P < 0.001), low-density lipoprotein cholesterol (LDL) (7.9 ± 25.1 mg/dL or 0.2 ± 0.65 mmol/L, P < 0.001), hemoglobin A1c (HgbA1c) (0.20 ± 0.64%, P = 0.001), insulin (3.8 ± 11 microU/ml or 26.6 ± 76.4 ρmol, P < 0.001) and ultra sensitive C-reactive protein (US - CRP) (0.9 ± 4.8 mg/dL or 7.3 ± 40.2 nmol/L, P = 0.012), an increase in mean high-density lipoprotein cholesterol (HDL) (3.7 ± 8.4 mg/dL or 0.1 ± 0.22, P < 0.001), and decreased use of medications.
Conclusion: Implementation of a comprehensive lifestyle modification program among adults with common chronic conditions results in significant and clinically meaningful improvements in biometric and laboratory outcomes after 6 months.
Figures


Similar articles
-
Comprehensive Lifestyle Modification Intervention to Improve Chronic Disease Risk Factors and Quality of Life in Cancer Survivors.J Altern Complement Med. 2018 Nov;24(11):1085-1091. doi: 10.1089/acm.2018.0193. Epub 2018 Aug 1. J Altern Complement Med. 2018. PMID: 30067063
-
Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.Clin Ther. 2008 Dec;30(12):2298-313. doi: 10.1016/j.clinthera.2008.12.023. Clin Ther. 2008. PMID: 19167589 Clinical Trial.
-
Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.Clin Ther. 2010 Mar;32(3):492-505. doi: 10.1016/j.clinthera.2010.03.018. Clin Ther. 2010. PMID: 20399986 Clinical Trial.
-
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.Endocr Pract. 2016 Jul;22 Suppl 3:1-203. doi: 10.4158/EP161365.GL. Epub 2016 May 24. Endocr Pract. 2016. PMID: 27219496
-
Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.Ann Intern Med. 1996 Oct 1;125(7):529-40. doi: 10.7326/0003-4819-125-7-199610010-00001. Ann Intern Med. 1996. PMID: 8815751 Clinical Trial.
Cited by
-
Interrelationship of canonical and non-canonical Wnt signalling pathways in chronic metabolic diseases.Diab Vasc Dis Res. 2018 Jan;15(1):3-13. doi: 10.1177/1479164117738442. Epub 2017 Nov 8. Diab Vasc Dis Res. 2018. PMID: 29113510 Free PMC article. Review.
-
Process Evaluation of a Nutrition and Lifestyle Behavior Peer Support Program for Adults with Metabolic Syndrome.Int J Environ Res Public Health. 2020 Apr 12;17(8):2641. doi: 10.3390/ijerph17082641. Int J Environ Res Public Health. 2020. PMID: 32290570 Free PMC article.
-
Development and Validation of a New Home Cooking Frequency Questionnaire: A Pilot Study.Nutrients. 2022 Mar 8;14(6):1136. doi: 10.3390/nu14061136. Nutrients. 2022. PMID: 35334793 Free PMC article.
-
Cultivating Healthier Habits: The Impact of Workplace Teaching Kitchens on Employee Food Literacy.Nutrients. 2024 Mar 16;16(6):865. doi: 10.3390/nu16060865. Nutrients. 2024. PMID: 38542775 Free PMC article.
-
Teaching Kitchens and Culinary Gardens as Integral Components of Healthcare Facilities Providing Whole Person Care: A Commentary.Nutrients. 2023 Sep 27;15(19):4162. doi: 10.3390/nu15194162. Nutrients. 2023. PMID: 37836446 Free PMC article.
References
-
- World Health Organization. Diet, Nutrition and the Prevention of Chronic Diseases. WHO Technical Report Series 916. 2003. - PubMed
-
- American College of Preventive Medicine: Lifestyle Medicine-Evidence Review. 2009. http://www.acpm.org/lifestyleMedicine.htm Accessed July 4, 2010.
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous